Source: https://www.scribd.com/document/217113373/Helsinn-Healthcare-Et-Al-v-Cipla-Et-Al
Timestamp: 2019-04-22 12:26:34+00:00

Document:
Helsinn Healthcare Et. Al. v. Cipla Et. Al.
Alpex Pharma et. al. v. Zydus Pharmaceuticals et. al.
Symantec v. RPost Holdings et. al.
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE HELSINN HEALTHCARE S.A.
pursuant to 28 U.S.C. 2201-02 because this case is an actual controversy within the Courts jurisdiction. 9. Venue is proper in this Court as to each Defendant pursuant to 28 U.S.C.
under 505(j)(2)(A)(vii)(IV) of the Federal Food, Drug and Cosmetic Act that the claims of the 218 patent are invalid, and that certain (but not all) of the claims are not infringed by ANDA No. 206396.
abetting, and/or inducement of the submission to the FDA of ANDA No. 206396 and the 505(j)(2)(A)(vii)(IV) certification constitutes infringement of the 219 patent under 35 U.S.C. 271(e)(2)(A).
Documents Similar To Helsinn Healthcare Et. Al. v. Cipla Et. Al.
Locata LBS v. Yellowpages.com et. al.
Andrea Electronics v. Lenovo Group Et. Al.
Andrea Electronics v. Toshiba Et. Al.
Global Tel*Link v. Securus Technologies et. al.
Impax Laboratories et. al. v. Lannett Holdings et. al.
Alkermes Pharma Ireland v. Sun Pharma Global FZE Et. Al.
Hologram Et. Al. v. Arena3D Industrial Illusion Et. Al.
Unimed Pharmaceuticals et. al. v. Perrigo Company et. al.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.